Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.37 |
| ▸ | BRD4 | O60885 | 15/20 | 0.35 |
| ▸ | TERT | O14746 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6591886 | 0.96 | BRD4 (0.37) | BRD4 | |
| SCHEMBL6594969 | 0.91 | MEN1 (0.36) | TLR9TLR8TLR7BRD4TERT | |
| SCHEMBL4081928 | 0.90 | BRD4 (0.32) | BRD4TERT | |
| SCHEMBL4074857 | 0.89 | TERT (0.35) | TERT | |
| SCHEMBL4076584 | 0.85 | TERT (0.33) | TERT | |
| SCHEMBL4082014 | 0.84 | ACVR1 (0.34) | TERT | |
| SCHEMBL6607149 | 0.84 | TERT (0.34) | TERT | |
| SCHEMBL6592153 | 0.81 | BMPR1B (0.38) | TLR9TLR8TLR7TERT | |
| SCHEMBL6605139 | 0.81 | TERT (0.33) | TERT | |
| SCHEMBL6594918 | 0.80 | MEN1 (0.37) | TLR9TLR8TLR7BRD4TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887873-B2 | Triazine derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2005-05-03 | — | — | US | claimed |
| EP-1373252-A1 | CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | Aventis Pharma S.A. (FR) | 2004-01-02 | — | — | EP | claimed |
| US-20030087931-A1 | Chemical derivatives and their application as antitelomerease agent | AVENTIS PHARMA S.A. (FR) | 2003-05-08 | — | — | US | claimed |
| WO-2002076975-A1 | CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | AVENTIS PHARMA S.A. (FR) | 2002-10-03 | — | — | WO | claimed |
| US-20090226411-A1 | CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS | AVENTIS PHARMA S.A. (FR) | 2009-09-10 | — | — | US | disclosed |
| US-7482352-B2 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2009-01-27 | — | — | US | disclosed |
| US-6887873-B2 | Triazine derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2005-05-03 | — | — | US | disclosed |
| US-20050070571-A1 | Chemical derivatives and their application as antitelomerase agents | AVENTIS PHARMA S.A. (FR) | 2005-03-31 | — | — | US | disclosed |
| EP-1373252-A1 | CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | Aventis Pharma S.A. (FR) | 2004-01-02 | — | — | EP | disclosed |
| US-20030087931-A1 | Chemical derivatives and their application as antitelomerease agent | AVENTIS PHARMA S.A. (FR) | 2003-05-08 | — | — | US | disclosed |
| WO-2002076975-A1 | CHEMICAL DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT | AVENTIS PHARMA S.A. (FR) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087931-A1 | Chemical derivatives and their application as antitelomerease agent | DNASE1L3, SERPINB1, BRDT | TLR9 4390/4885TLR8 4503/4885TLR7 4740/4885 |
| US-20090226411-A1 | CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS | DPYD, NTPCR, NME1 | TLR9 4767/4885TLR8 4360/4885TLR7 4774/4885 |
| US-20050070571-A1 | Chemical derivatives and their application as antitelomerase agents | DPYD, NTPCR, NME1 | TLR9 4767/4885TLR8 4360/4885TLR7 4774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.